Cargando…
Antidepressant prescribing in the precision medicine era: a prescriber’s primer on pharmacogenetic tools
About half of people who take antidepressants do not respond and many experience adverse effects. These detrimental outcomes are in part a result of the impact of an individual’s genetic profile on pharmacokinetics and pharmcodynamics. If known and made available to clinicians, this could improve de...
Autores principales: | Bousman, Chad A., Forbes, Malcolm, Jayaram, Mahesh, Eyre, Harris, Reynolds, Charles F., Berk, Michael, Hopwood, Malcolm, Ng, Chee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299682/ https://www.ncbi.nlm.nih.gov/pubmed/28178974 http://dx.doi.org/10.1186/s12888-017-1230-5 |
Ejemplares similares
-
CYP2D6 and CYP2C19 Variant Coverage of Commercial Antidepressant Pharmacogenomic Testing Panels Available in Victoria, Australia
por: Forbes, Malcolm, et al.
Publicado: (2023) -
Editorial: Precision psychiatry from a pharmacogenetics perspective
por: Brown, Lisa C., et al.
Publicado: (2023) -
“Black box” pharmacogenetic decision-support tools in psychiatry
por: Bousman, Chad A., et al.
Publicado: (2020) -
Sequence2Script: A Web-Based Tool for Translation of Pharmacogenetic Data Into Evidence-Based Prescribing Recommendations
por: Bousman, Chad A., et al.
Publicado: (2021) -
Antidepressant prescribing patterns in Australia
por: Malhi, Gin S., et al.
Publicado: (2022)